Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma
Current Oncology · 2024
DOI: 10.3390/curroncol31040129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Kosuke Ueda und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kurume University School of Medicine, Kurume 830-0011, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JPSS KAKENHI.
Abstract (Originalsprache)
Immuno-oncology (IO) combination therapy is the first-line treatment for advanced renal cell carcinoma (RCC). However, biomarkers for predicting the response to IO combination therapy are lacking. Here, we investigated the association between the expression of soluble immune checkpoint molecules and the therapeutic efficacy of IO combination therapy in advanced RCC. The expression of soluble programmed cell death-1 (sPD-1), soluble programmed cell death ligand-1 (sPD-L1), soluble PD-L2 (sPD-L2), and lymphocyte activation gene-3 (sLAG-3) was assessed in plasma samples from 42 patients with advanced RCC who received first-line IO combination therapy. All IMDC risk classifications were represented among the patients, including 14.3, 57.1, and 28.6% with favorable, intermediate, and poor risk, respectively. Univariate analysis revealed that prior nephrectomy, sPD-L2 levels, and sLAG-3 levels were significant factors affecting progression-free survival (PFS), whereas multivariate analyses suggested that sPD-L2 and sLAG-3 levels were independent prognostic factors for PFS. In a univariate analysis of the overall survival, prior nephrectomy and sPD-L2 levels were significant factors; no significant differences were observed in the multivariate analysis. No significant correlation was observed between the sPD-L2 and sLAG-3 levels and PD-L2 and LAG-3 expression via immunohistochemistry. In conclusion, sPD-L2 and sLAG-3 expression may serve as a potential biomarker for predicting IO combination therapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kurume University School of Medicine, Kurume 830-0011, Japan.
- Department of Pathology, Kurume University School of Medicine, Kurume 830-0011, Japan.
ORCID-Profile: Kosuke Ueda, Makoto Nakiri
Förderung
- JPSS KAKENHI
Zitieren
APA
Ueda, K., Uemura, K., Ito, N., Sakai, Y., Ohnishi, S., Suekane, H., Kurose, H., Hiroshige, T., Chikui, K., Nishihara, K., Nakiri, M., Suekane, S., Ogasawara, S., Yano, H., & Igawa, T. (2024). Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma. Current Oncology. https://doi.org/10.3390/curroncol31040129
Vancouver
Ueda K, Uemura K, Ito N, Sakai Y, Ohnishi S, Suekane H, et al. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma. Current Oncology. 2024. doi:10.3390/curroncol31040129
BibTeX
@article{Ueda2024,
author = {Ueda, Kosuke and Uemura, Keiichiro and Ito, Naoki and Sakai, Yuya and Ohnishi, Satoshi and Suekane, Hiroki and Kurose, Hirofumi and Hiroshige, Tasuku and Chikui, Katsuaki and Nishihara, Kiyoaki and Nakiri, Makoto and Suekane, Shigetaka and Ogasawara, Sachiko and Yano, Hirohisa and Igawa, Tsukasa},
title = {Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31040129}
}
EUVIMED